
Pacific Biosciences California (PACB) Stock
Long read DNA sequencer maker for research and medicine. Here's the price, business snapshot, and what's worth knowing about Pacific Biosciences California in November 2026.
Pacific Biosciences of California, Inc. (PACB) develops long‑read DNA sequencing systems and consumables used in genomics research and translational science. Its platforms produce high‑accuracy long reads that help assemble complex genomes, call structural variants and support applications across human genetics, agricultural genomics and drug discovery. Revenue is driven by sales of instruments, recurring consumables, service agreements and software. With a market capitalisation of about $570.70m, PACB is a small‑cap, growth‑oriented company and its shares can be volatile. Key considerations for investors include product adoption, the recurring consumable revenue stream, competitive dynamics with short‑ and long‑read sequencing rivals, and the company’s pathway to sustainable profitability. Operational risks include execution on commercial roll‑out, supply‑chain constraints and R&D outcomes. This is general educational information only and not personal investment advice; values can rise and fall and past performance does not predict future returns.
Pacific Biosciences California (PACB) Stock Forecast
Analyst price target, next 12 months
$2.76
+38.2% vs today's $2.00
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Pacific Biosciences California have a consensus 12-month target of $2.76, above the current price of $2.00.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 13 Nov 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Pacific Biosciences stock, anticipating it could rise to $2.76.
Financial Health
Pacific Biosciences is generating solid revenue and cash flow, reflecting a healthy financial position.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Long‑read sequencing
Unique long‑read technology can resolve complex genomic regions and structural variants, which attracts research and clinical interest — though adoption and commercial scale‑up can take time.
Product innovation
Newer, higher‑throughput systems aim to broaden addressable markets and improve per‑sample economics, but execution and competitive responses are important risks to monitor.
Research and markets
Used across human health, pharmaceuticals and agriculture, offering diverse end markets; revenues can be cyclical and are sensitive to institutional capital spending.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.